A detailed history of Massachusetts Financial Services CO transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 765,692 shares of COLL stock, worth $22.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
765,692
Previous 649,365 17.91%
Holding current value
$22.3 Million
Previous $20.9 Million 41.5%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$31.4 - $39.07 $3.65 Million - $4.54 Million
116,327 Added 17.91%
765,692 $29.6 Million
Q2 2024

Aug 09, 2024

SELL
$31.36 - $39.99 $389,898 - $497,195
-12,433 Reduced 1.88%
649,365 $20.9 Million
Q1 2024

May 14, 2024

SELL
$31.23 - $40.91 $103,683 - $135,821
-3,320 Reduced 0.5%
661,798 $25.7 Million
Q4 2023

Feb 08, 2024

BUY
$21.16 - $30.8 $12,674 - $18,449
599 Added 0.09%
665,118 $20.5 Million
Q3 2023

Nov 08, 2023

BUY
$21.23 - $24.28 $24,117 - $27,582
1,136 Added 0.17%
664,519 $14.9 Million
Q2 2023

Aug 09, 2023

SELL
$21.06 - $24.0 $128,550 - $146,496
-6,104 Reduced 0.91%
663,383 $14.3 Million
Q1 2023

May 10, 2023

SELL
$23.0 - $29.88 $3.45 Million - $4.49 Million
-150,125 Reduced 18.32%
669,487 $16.1 Million
Q4 2022

Feb 13, 2023

BUY
$16.14 - $23.55 $43,352 - $63,255
2,686 Added 0.33%
819,612 $19 Million
Q3 2022

Nov 09, 2022

SELL
$15.46 - $20.1 $825,254 - $1.07 Million
-53,380 Reduced 6.13%
816,926 $13.1 Million
Q2 2022

Aug 09, 2022

BUY
$14.22 - $20.88 $78,551 - $115,341
5,524 Added 0.64%
870,306 $15.4 Million
Q1 2022

May 11, 2022

BUY
$17.2 - $22.5 $385,297 - $504,022
22,401 Added 2.66%
864,782 $17.6 Million
Q4 2021

Feb 10, 2022

BUY
$17.5 - $21.35 $361,095 - $440,535
20,634 Added 2.51%
842,381 $15.7 Million
Q3 2021

Nov 10, 2021

SELL
$17.75 - $25.39 $191,824 - $274,389
-10,807 Reduced 1.3%
821,747 $16.2 Million
Q2 2021

Aug 13, 2021

BUY
$21.74 - $25.28 $4.11 Million - $4.78 Million
189,232 Added 29.41%
832,554 $19.7 Million
Q1 2021

May 13, 2021

SELL
$19.25 - $26.1 $316,027 - $428,483
-16,417 Reduced 2.49%
643,322 $15.2 Million
Q4 2020

Feb 12, 2021

BUY
$17.83 - $22.29 $177,230 - $221,562
9,940 Added 1.53%
659,739 $13.2 Million
Q3 2020

Nov 12, 2020

SELL
$15.78 - $20.82 $270,137 - $356,417
-17,119 Reduced 2.57%
649,799 $13.5 Million
Q2 2020

Aug 11, 2020

BUY
$15.49 - $23.51 $2.84 Million - $4.31 Million
183,352 Added 37.92%
666,918 $11.7 Million
Q1 2020

May 14, 2020

SELL
$13.89 - $25.45 $146,845 - $269,057
-10,572 Reduced 2.14%
483,566 $7.9 Million
Q4 2019

Feb 13, 2020

SELL
$10.7 - $22.24 $1.01 Million - $2.09 Million
-94,007 Reduced 15.98%
494,138 $10.2 Million
Q3 2019

Nov 05, 2019

SELL
$10.16 - $13.28 $22,829 - $29,840
-2,247 Reduced 0.38%
588,145 $6.75 Million
Q2 2019

Aug 14, 2019

BUY
$10.62 - $16.59 $36,639 - $57,235
3,450 Added 0.59%
590,392 $7.76 Million
Q1 2019

May 13, 2019

SELL
$13.58 - $18.72 $1.04 Million - $1.43 Million
-76,556 Reduced 11.54%
586,942 $8.89 Million
Q4 2018

Feb 08, 2019

BUY
$14.78 - $19.68 $205,057 - $273,040
13,874 Added 2.14%
663,498 $11.4 Million
Q3 2018

Oct 25, 2018

BUY
$14.16 - $24.3 $3.26 Million - $5.59 Million
229,968 Added 54.8%
649,624 $9.58 Million
Q2 2018

Jul 30, 2018

BUY
$21.79 - $28.29 $126,774 - $164,591
5,818 Added 1.41%
419,656 $10 Million
Q1 2018

May 04, 2018

SELL
$18.15 - $29.21 $643,000 - $1.03 Million
-35,427 Reduced 7.89%
413,838 $10.6 Million
Q4 2017

Feb 14, 2018

SELL
$9.3 - $19.14 $2.08 Million - $4.28 Million
-223,362 Reduced 33.21%
449,265 $8.29 Million
Q3 2017

Nov 14, 2017

BUY
$9.15 - $11.97 $37,231 - $48,705
4,069 Added 0.61%
672,627 $7.06 Million
Q2 2017

Aug 14, 2017

BUY
N/A
668,558
668,558 $8.36 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $993M
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.